Overview / Abstract: |
Rapid progress in the treatment of Acute Myeloid Leukemia (AML) has resulted in a substantial volume of new clinical literature and updated guidelines. 8 new therapies have been approved since 2017 alone. Clinicians must remain well-versed with novel treatment options for newly diagnosed patients and those with relapsed/refractory AML and need education on advances in targeted therapies for AML. This expert live recording from a series of national visiting lecture series updates clinicians on the latest data from clinical trials and provides direction on integrating novel treatment strategies based on patient and disease characteristics into their practice. This activity also includes a downloadable resource to improve care for your AML patients featuring slides from the national visiting lecture series. |
Expiration |
Apr 22, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.00 |
Accreditation |
ACCME |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
Naval Daver, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. |
Keywords / Search Terms |
ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Webcasts, Newsletter, Case Study, Live Meetings, Slidekit, Monograph, Journal, CPX-351, liposomal, cytarabine, daunorubicin, chemotherapy, t-AML, SEAMLESS study, Tyrosine kinase inhibitors, CALGB 10603 trial, relapsed AML, refractory AML, Naval Daver, MD, Gilteritinib, ADMIRAL trial, Enasidenib, venetoclax, Ivosidenib, azacytidine, IDH1 mutation, FLT3, NPM1, DNMT3a, IDH1, IDH2, TET2, RUNX1, p53, NRAS, CEBPa, WT1, Midostaurin, Gemtuzumab ozogamicin, Immunophenotyping, cytogenic testing, molecular testing Free CE CME Live CE CME |